Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies

被引:11
|
作者
Weichseldorfer, Matthew [1 ]
Tagaya, Yutaka [1 ,2 ]
Reitz, Marvin [1 ,2 ]
DeVico, Anthony L. [1 ,2 ]
Latinovic, Olga S. [1 ,3 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
关键词
HIV; AIDS pathogenesis; CCR5 coreceptor populations; Conformational changes; PRIMARY-CELLS IMPLICATIONS; CHEMOKINE RECEPTOR CCR5; PROTEIN FLSC IGG1; R5; HIV-1; SYNERGISTIC INHIBITION; MARAVIROC; INDIVIDUALS; MECHANISMS; RESISTANT; SURFACE;
D O I
10.1186/s12967-022-03243-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The chemokine receptor CCR5 is the major coreceptor for HIV-1 cell entry. We previously observed that not all CCR5 mAbs reduce HIV-1 infection, suggesting that only some CCR5 populations are permissive for HIV-1 entry. This study aims to better understand the relevant conformational states of the cellular coreceptor, CCR5, involved in HIV entry. We hypothesized that CCR5 assumes multiple configurations during normal cycling on the plasma membrane, but only particular forms facilitate HIV-1 infection. Methods To this end, we quantified different CCR5 populations using six CCR5 monoclonal antibodies (mAbs) with different epitope specificities and visualized them with super-resolution microscopy. We quantified each surface CCR5 population before and after HIV-1 infection. Results Based on CCR5 conformational changes, down-modulation, and trafficking rates (internalization and recycling kinetics), we were able to distinguish among heterogeneous CCR5 populations and thus which populations might best be targeted to inhibit HIV-1 entry. We assume that a decreased surface presence of a particular CCR5 subpopulation following infection means that it has been internalized due to HIV-1 entry, and that it therefore represents a highly relevant target for future antiviral therapy strategies. Strikingly, this was most true for antibody CTC8, which targets the N-terminal region of CCR5 and blocks viral entry more efficiently than it blocks chemokine binding. Conclusions Defining the virus-host interactions responsible for HIV-1 transmission, including specific coreceptor populations capable of establishing de novo infections, is essential for the development of an HIV-1 vaccine. This study hopefully will facilitate further development of inhibitors to block CCR5 usage by HIV-1, as well as inform future HIV-1 vaccine design.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] CCR5 genotype and resistance to vertical transmission of HIV-1
    Philpott, S
    Burger, H
    Charbonneau, T
    Grimson, R
    Vermund, SH
    Visosky, A
    Nachman, S
    Kovacs, A
    Tropper, P
    Frey, H
    Weiser, B
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 189 - 193
  • [32] Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5)
    Ruff, MR
    Melendez-Guerrero, LM
    Yang, QE
    Ho, WZ
    Mikovits, JW
    Pert, CB
    Ruscetti, FA
    ANTIVIRAL RESEARCH, 2001, 52 (01) : 63 - 75
  • [33] Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection
    Li, Hui
    Liu, Ting-Jun
    Hong, Ze-Hui
    INFECTION GENETICS AND EVOLUTION, 2014, 24 : 99 - 104
  • [34] Suppression of Active HIV-1 Infection in CD34+ Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs
    Latinovic, Olga S.
    Neal, Lauren M.
    Tagaya, Yutaka
    Heredia, Alonso
    Medina-Moreno, Sandra
    Zapata, Juan C.
    Reitz, Marvin
    Bryant, Joseph
    Redfield, Robert R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2019, 35 (08) : 718 - 728
  • [35] Grafting segments from the extracellular surface of CCR5 onto a bacteriorhodopsin transmembrane scaffold confers HIV-1 coreceptor activity
    Abdulaev, NG
    Strassmaier, TT
    Ngo, T
    Chen, RW
    Luecke, H
    Oprian, DD
    Ridge, KD
    STRUCTURE, 2002, 10 (04) : 515 - 525
  • [36] R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies
    Lamorris M Loftin
    Martha Kienzle
    Yanjie Yi
    Ronald G Collman
    Journal of Translational Medicine, 9
  • [37] R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies
    Loftin, Lamorris M.
    Kienzle, Martha
    Yi, Yanjie
    Collman, Ronald G.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9
  • [38] Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5
    Berg, Christian
    Spiess, Katja
    Luttichau, Hans R.
    Rosenkilde, Mette M.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2016, 4 (06):
  • [39] Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5
    Appiah-Kubi, Patrick
    Iwuchukwu, Emmanuel Amarachi
    Soliman, Mahmoud E. S.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (23) : 13115 - 13126
  • [40] A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5
    Zhao, Q
    He, YX
    Alespeiti, G
    Debnath, AK
    VIROLOGY, 2004, 326 (02) : 299 - 309